Dibromoacetic acid


Literature identifierStudy typeTest dosageEffective dosageEndocrine-mediated endpointsSystems-level perturbations
PMID:15808788IVR150 mg/L 150 mg/LIncreased weights of pituitary glandNeurological endocrine-mediated perturbations
IVR150 mg/L 150 mg/LIncreased estrone levelsReproductive endocrine-mediated perturbations
IVR150 mg/L 150 mg/LIncreased liver weightsHepatic endocrine-mediated perturbations
IVR50 mg/L 50 mg/LIncreased estrone levelsReproductive endocrine-mediated perturbations
IVR50 mg/L 50 mg/LIncreased weights of pituitary glandNeurological endocrine-mediated perturbations
IVR300 mg/L 300 mg/LIncreased weights of pituitary glandNeurological endocrine-mediated perturbations
IVR300 mg/L 300 mg/LIncreased liver weightsHepatic endocrine-mediated perturbations
IVR300 mg/L 300 mg/LIncreased estrone levelsReproductive endocrine-mediated perturbations
PMID:9138633IVR250 mg/kg 250 mg/kgAtrophy in seminiferous tubulesReproductive endocrine-mediated perturbations
IVR250 mg/kg 250 mg/kgAlterations in number of sertoli cellsReproductive endocrine-mediated perturbations
IVR250 mg/kg 250 mg/kgAbnormal sperm morphologyReproductive endocrine-mediated perturbations

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.